Medpace (NASDAQ:MEDP) Director Sells 1,140 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Cornelius Mccarthy III sold 1,140 shares of Medpace stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director directly owned 12,275 shares of the company’s stock, valued at $7,430,916.75. The trade was a 8.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Stock Down 2.5%

MEDP traded down $15.03 on Thursday, hitting $581.95. The company had a trading volume of 151,058 shares, compared to its average volume of 353,878. The company has a market cap of $16.24 billion, a PE ratio of 34.11, a PEG ratio of 2.70 and a beta of 1.15. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The business’s fifty day simple moving average is $531.28 and its 200 day simple moving average is $491.78.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent analyst reports. BMO Capital Markets lifted their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen boosted their target price on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. bought a new position in Medpace in the second quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Elyxium Wealth LLC bought a new position in shares of Medpace during the 4th quarter worth $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace during the second quarter valued at $31,000. Finally, Kilter Group LLC bought a new stake in shares of Medpace in the second quarter valued at about $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.